世界の核医学機器市場は、2025年の66億3000万ドルから2030年には83億1000万ドルに成長し、2025年から2030年の間にCAGRは4.62%になると予測されます。このレポートでは、Hermes Medical Solutions(スウェーデン)、DOSIsoft(フランス)、Segami Corporation(米国)、GE HealthCare(米国)、Siemens Healthineers AG(ドイツ)、Koninklijke Philips N.V.(オランダ)、キヤノンメディカルシステムズ(日本)などの主要企業を紹介しています。
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Breakdown of primary interviews
2.1.2.4 Insights from primary experts
2.2 RESEARCH METHODOLOGY
2.3 MARKET SIZE ESTIMATION
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 MARKET SHARE ESTIMATION
2.6 RESEARCH ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 OVERVIEW OF NUCLEAR MEDICINE EQUIPMENT MARKET
4.2 ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA
4.3 GEOGRAPHIC SNAPSHOT OF NUCLEAR MEDICINE EQUIPMENT MARKET
4.4 NUCLEAR MEDICINE EQUIPMENT MARKET: REGIONAL MIX
4.5 NUCLEAR MEDICINE EQUIPMENT MARKET: DEVELOPED VS. EMERGING MARKETS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rapid expansion of theranostics
5.2.1.2 Technological advancements in hybrid imaging modalities
5.2.1.3 Favorable government support and expanding healthcare infrastructure
5.2.1.4 Advancements in radiotracers and radiopharmaceuticals
5.2.1.5 Integration of AI into nuclear medicine equipment
5.2.2 RESTRAINTS
5.2.2.1 Capital-intensive nature of equipment
5.2.2.2 Short half-life of radiopharmaceuticals
5.2.2.3 High maintenance and operational costs
5.2.2.4 Shortage of trained personnel
5.2.3 OPPORTUNITIES
5.2.3.1 Growing preference for personalized and precision medicine
5.2.3.2 Telemedicine and cloud-native platforms & mobile/remote imaging capabilities
5.2.4 CHALLENGES
5.2.4.1 Global isotope supply chain instability
5.2.4.2 Cybersecurity and data privacy issues in imaging IT
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 INDUSTRY TRENDS
5.4.1 SHIFT TOWARD HYBRID AND MULTI-MODALITY IMAGING SYSTEMS
5.4.2 ADVANCEMENTS IN DETECTOR TECHNOLOGIES AND IMAGE QUALITY
5.4.3 GROWING DEMAND FOR COMPACT AND VERSATILE SYSTEMS
5.4.4 INTEGRATION OF ARTIFICIAL INTELLIGENCE AND AUTOMATION
5.4.5 CONNECTIVITY AND CLOUD-ENABLED WORKFLOWS
5.5 PRICING ANALYSIS
5.5.1 INTRODUCTION
5.5.2 INDICATIVE PRICE OF NUCLEAR MEDICINE EQUIPMENT, BY KEY PLAYER
5.5.3 INDICATIVE PRICE OF NUCLEAR MEDICINE EQUIPMENT, BY REGION
5.5.4 AVERAGE SELLING PRICE OF NUCLEAR CARDIOLOGY REPORTING SOFTWARE
5.5.5 PRICING MODELS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Hybrid imaging systems
5.9.1.2 Digital detection technology
5.9.1.3 Artificial Intelligence (AI) and advanced image reconstruction techniques
5.9.1.4 Time-of-Flight (TOF) technology
5.9.1.5 Solid-state detector technology
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Radiopharmaceutical development and theranostics
5.9.2.2 Advanced computing and big data analytics
5.9.2.3 Robotics and automated dose dispensing systems
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Magnetic Resonance Imaging (MRI) integration
5.9.3.2 Computed Tomography (CT) advancements
5.10 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA FOR HS CODE 901814
5.11.2 EXPORT DATA FOR HS CODE 901814
5.12 KEY CONFERENCES AND EVENTS, 2025-2026
5.13 CASE STUDY ANALYSIS
5.13.1 PRECISION IN NUCLEAR MEDICINE WITH NATIONAL STANDARD TRACEABILITY
5.13.2 MULTI-MODALITY IMAGE FUSION FOR IMPROVED DIAGNOSTICS
5.13.3 REMOTE CONSULTATION WITH CLOUD-BASED NUCLEAR MEDICINE ANALYSIS
5.14 TARIFF AND REGULATORY LANDSCAPE
5.14.1 TARIFF DATA FOR HS CODE 901814
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14.3 REGULATORY ANALYSIS
5.15 PORTER'S FIVE FORCES ANALYSIS
5.15.1 BARGAINING POWER OF SUPPLIERS
5.15.2 BARGAINING POWER OF BUYERS
5.15.3 THREAT OF NEW ENTRANTS
5.15.4 THREAT OF SUBSTITUTES
5.15.5 INTENSITY OF COMPETITIVE RIVALRY
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.16.2 BUYING CRITERIA
5.17 END-USER ANALYSIS
5.17.1 UNMET NEEDS
5.17.2 END-USER EXPECTATIONS
5.18 BUSINESS MODEL
5.18.1 DIRECT EQUIPMENT SALES MODEL
5.18.2 SERVICE AND MAINTENANCE CONTRACTS
5.18.3 PAY-PER-SCAN (OR PAY-PER-USE) MODEL
5.18.4 EQUIPMENT LEASING AND FINANCING SOLUTIONS
5.18.5 INTEGRATED SOLUTIONS AND MANAGED SERVICES
5.18.6 SOFTWARE AND DATA ANALYTICS SUBSCRIPTION
5.19 IMPACT OF AI/GEN AI
5.19.1 INTRODUCTION
5.19.2 MARKET POTENTIAL OF AI/GEN AI
5.19.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
5.19.3.1 AI-based low-dose PET image reconstruction
5.19.3.2 Dose-aware diffusion models for 3D low-dose PET
5.19.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
5.19.4.1 Medical image analysis software
5.19.4.2 Radiology information systems
5.19.4.3 Clinical decision support systems
5.19.5 USER READINESS AND IMPACT ASSESSMENT
5.19.5.1 User readiness
5.19.5.1.1 User A: Hospitals
5.19.5.1.2 User B: Diagnostic imaging centers
5.19.5.2 Impact assessment
5.19.5.2.1 User A: Hospitals
5.19.5.2.2 User B: Diagnostic imaging centers
5.20 IMPACT OF 2025 US TARIFF - OVERVIEW
5.20.1 INTRODUCTION
5.20.2 KEY TARIFF RATES
5.20.3 PRICE IMPACT ANALYSIS
5.20.3.1 Capital equipment (cyclotrons, PET/SPECT systems)
5.20.3.2 Gamma cameras
5.20.3.3 Key materials: semiconductors, detectors, shielding
5.20.3.4 Service parts, maintenance, and global supply chains
5.20.4 IMPACT ON COUNTRY/REGION
5.20.4.1 US
5.20.4.2 Europe
5.20.4.3 Asia Pacific
5.20.5 IMPACT ON END-USE INDUSTRIES
5.20.5.1 Hospitals
5.20.5.2 Diagnostic imaging centers
5.20.5.3 Cancer treatment centers
5.20.5.4 Other end users
5.20.6 CONCLUSION
6 NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE
6.1 INTRODUCTION
6.2 IMAGING MODALITIES
6.2.1 PET
6.2.1.1 Standalone PET
6.2.1.1.1 Increasing demand for cost-efficient, high-throughput oncological imaging to boost market
6.2.1.2 Hybrid PET
6.2.1.2.1 Ability to provide functional and anatomical information in single scan to aid growth
6.2.2 SPECT
6.2.2.1 Standalone SPECT
6.2.2.1.1 Wide use in thyroid studies, renal scans, and bone imaging to encourage growth
6.2.2.2 Hybrid SPECT
6.2.2.2.1 Need for improved diagnostic accuracy and clinical confidence to propel market
6.2.3 GAMMA/SCINTILLATION CAMERAS
6.2.3.1 Clinical versatility and lower cost to expedite growth
6.3 NON-IMAGING MODALITIES
6.3.1 GM COUNTERS
6.3.1.1 Ease of use, portability, and critical role in maintaining workplace safety to spur growth
6.3.2 DOSE CALIBRATORS
6.3.2.1 Increasing development in digital interfaces, automatic isotope recognition, and real-time data logging to bolster growth
6.3.3 PROBE COUNTING SYSTEMS
6.3.3.1 Technological advancements in probe counting systems to contribute to growth
6.3.4 GAMMA WELL COUNTERS
6.3.4.1 Growing use of gamma well counters in laboratory-based applications to propel market
6.3.5 OTHER NON-IMAGING MODALITIES
7 NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA
7.1 INTRODUCTION
7.2 ONCOLOGY
7.2.1 IMPROVEMENTS IN IMAGING ACCURACY AND TREATMENT PLANNING TO STIMULATE GROWTH
7.3 NEUROLOGY
7.3.1 ESCALATING GLOBAL BURDEN OF NEURODEGENERATIVE DISORDERS AND OTHER NEUROLOGICAL CONDITIONS TO AID GROWTH
7.4 CARDIOLOGY
7.4.1 PERSISTENT GLOBAL BURDEN OF CARDIOVASCULAR DISEASES TO FACILITATE GROWTH
7.5 ORTHOPEDICS
7.5.1 GROWING PREVALENCE OF DEGENERATIVE JOINT DISEASES, SPORTS INJURIES, AND OSTEOPOROSIS TO BOOST MARKET
7.6 THYROID
7.6.1 GLOBAL PREVALENCE OF HYPER- AND HYPOTHYROIDISM AND THYROID CANCER TO AUGMENT GROWTH
7.7 OTHER THERAPEUTIC AREAS
8 NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION
8.1 INTRODUCTION
8.2 2D
8.2.1 WIDE AVAILABILITY, EASE OF INTEGRATION, AND ESTABLISHED PRESENCE IN CLINICAL WORKFLOW TO AID GROWTH
8.3 3D
8.3.1 GROWING RELIANCE ON ADVANCED IMAGING TECHNOLOGIES TO FUEL MARKET
9 NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER
9.1 INTRODUCTION
9.2 HOSPITALS
9.2.1 CONTINUOUS TECHNOLOGICAL ADVANCEMENTS TO FOSTER GROWTH
9.3 DIAGNOSTIC IMAGING CENTERS
9.3.1 GROWING DEMAND FOR EARLY AND PRECISE DIAGNOSIS TO DRIVE MARKET
9.4 CANCER TREATMENT CENTERS
9.4.1 ESCALATING GLOBAL INCIDENCE OF CANCER TO PROMOTE GROWTH
9.5 OTHER END USERS
10 NUCLEAR MEDICINE EQUIPMENT MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.2.1 Advancements in PET and SPECT equipment for personalized care to aid growth
10.2.3 CANADA
10.2.3.1 Increasing adoption of advanced imaging technologies to support growth
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 GERMANY
10.3.2.1 Increasing adoption of hybrid imaging systems to spur growth
10.3.3 UK
10.3.3.1 Favorable clinical guidelines supporting wider use of PET-CT to fuel market
10.3.4 FRANCE
10.3.4.1 Shift to hybrid imaging to accelerate growth
10.3.5 ITALY
10.3.5.1 Robust network of scanners to facilitate growth
10.3.6 SPAIN
10.3.6.1 Growing integration of cutting-edge technologies into clinical practice to propel market
10.3.7 SWEDEN
10.3.7.1 Rapid shift toward PET procedures to accelerate growth
10.3.8 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 JAPAN
10.4.2.1 Ongoing innovations in equipment and growing reliance on nuclear imaging for accurate detection to drive market
10.4.3 CHINA
10.4.3.1 Rapid investments in medical infrastructure and technological advancements in image analysis to spur growth
10.4.4 INDIA
10.4.4.1 Substantial cancer and cardiovascular disease burden to encourage growth
10.4.5 SOUTH KOREA
10.4.5.1 Universal health coverage to bolster growth
10.4.6 AUSTRALIA
10.4.6.1 Strong diagnostic imaging network and widespread adoption of hybrid imaging technologies to contribute to growth
10.4.7 REST OF ASIA PACIFIC
10.5 MIDDLE EAST & AFRICA
10.5.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
10.5.2 GCC COUNTRIES
10.5.2.1 Growing healthcare needs and favorable government support to boost market
10.5.3 REST OF MIDDLE EAST & AFRICA
10.6 LATIN AMERICA
10.6.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.6.2 BRAZIL
10.6.2.1 Healthcare modernization efforts to accelerate growth
10.6.3 MEXICO
10.6.3.1 Expanding healthcare infrastructure to bolster growth
10.6.4 REST OF LATIN AMERICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEAR MEDICINE EQUIPMENT MARKET
11.3 REVENUE ANALYSIS, 2020-2024
11.4 MARKET SHARE ANALYSIS, 2024
11.4.1 POSITRON EMISSION TOMOGRAPHY (PET) EQUIPMENT
11.4.2 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) EQUIPMENT
11.5 MARKET RANKING ANALYSIS
11.6 BRAND/PRODUCT COMPARISON
11.7 COMPANY VALUATION AND FINANCIAL METRICS
11.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
11.8.1 STARS
11.8.2 EMERGING LEADERS
11.8.3 PERVASIVE PLAYERS
11.8.4 PARTICIPANTS
11.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
11.8.5.1 Company footprint
11.8.5.2 Region footprint
11.8.5.3 System type footprint
11.8.5.4 Therapeutic area footprint
11.8.5.5 Dimension footprint
11.8.5.6 End-user footprint
11.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
11.9.1 PROGRESSIVE COMPANIES
11.9.2 RESPONSIVE COMPANIES
11.9.3 DYNAMIC COMPANIES
11.9.4 STARTING BLOCKS
11.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
11.9.5.1 Detailed list of key startups/SMEs
11.9.5.2 Competitive benchmarking of startups/SMEs
11.10 COMPETITIVE SCENARIO
11.10.1 PRODUCT LAUNCHES AND APPROVALS
11.10.2 DEALS
11.10.3 EXPANSIONS
11.10.4 OTHER DEVELOPMENTS
12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 GE HEALTHCARE
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 Recent developments
12.1.1.3.1 Product launches and approvals
12.1.1.3.2 Deals
12.1.1.3.3 Expansions
12.1.1.4 MnM view
12.1.1.4.1 Right to win
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses and competitive threats
12.1.2 SIEMENS HEALTHINEERS AG
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 Recent developments
12.1.2.3.1 Product launches and approvals
12.1.2.3.2 Deals
12.1.2.4 MnM view
12.1.2.4.1 Right to win
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses and competitive threats
12.1.3 KONINKLIJKE PHILIPS N.V.
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 Recent developments
12.1.3.3.1 Product launches and approvals
12.1.3.3.2 Deals
12.1.3.4 MnM view
12.1.3.4.1 Right to win
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses and competitive threats
12.1.4 MIRION TECHNOLOGIES, INC.
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 Recent developments
12.1.4.3.1 Product launches and approvals
12.1.4.3.2 Deals
12.1.4.4 MnM view
12.1.4.4.1 Right to win
12.1.4.4.2 Strategic choices
12.1.4.4.3 Weaknesses and competitive threats
12.1.5 CANON MEDICAL SYSTEMS CORPORATION
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.5.3 Recent developments
12.1.5.3.1 Deals
12.1.5.4 MnM view
12.1.5.4.1 Right to win
12.1.5.4.2 Strategic choices
12.1.5.4.3 Weaknesses and competitive threats
12.1.6 HERMES MEDICAL SOLUTIONS
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.6.3 Recent developments
12.1.6.3.1 Product launches and approvals
12.1.6.3.2 Deals
12.1.6.3.3 Other developments
12.1.7 DOSISOFT SA
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.7.3 Recent developments
12.1.7.3.1 Product launches and approvals
12.1.7.3.2 Deals
12.1.8 SEGAMI CORPORATION
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.9 WINKGEN MEDICAL SYSTEMS GMBH & CO. KG
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.9.3 Recent developments
12.1.9.3.1 Product launches and approvals
12.1.9.3.2 Deals
12.1.10 COMECER S.P.A.
12.1.10.1 Business overview
12.1.10.2 Products offered
12.1.10.3 Recent developments
12.1.10.3.1 Product launches and approvals
12.1.10.3.2 Deals
12.1.10.3.3 Expansions
12.1.11 SYNTERMED INC.
12.1.11.1 Business overview
12.1.11.2 Products offered
12.1.11.3 Recent developments
12.1.11.3.1 Deals
12.1.12 ULTRASPECT INC.
12.1.12.1 Business overview
12.1.12.2 Products offered
12.1.13 LABLOGIC SYSTEMS LTD.
12.1.13.1 Business overview
12.1.13.2 Products offered
12.1.13.3 Recent developments
12.1.13.3.1 Product launches and approvals
12.1.13.3.2 Deals
12.1.13.3.3 Expansions
12.1.14 MEDISO LTD.
12.1.14.1 Business overview
12.1.14.2 Products offered
12.1.14.3 Recent developments
12.1.14.3.1 Product launches and approvals
12.1.15 CATALYST MEDTECH
12.1.15.1 Business overview
12.1.15.2 Products offered
12.1.15.3 Recent developments
12.1.15.3.1 Deals
12.1.15.3.2 Other developments
12.1.16 LEMER PAX
12.1.16.1 Business overview
12.1.16.2 Products offered
12.1.16.3 Recent developments
12.1.16.3.1 Product launches and approvals
12.1.16.3.2 Deals
12.1.17 SPECTRUM DYNAMICS MEDICAL
12.1.17.1 Business overview
12.1.17.2 Products offered
12.1.17.3 Recent developments
12.1.17.3.1 Product launches and approvals
12.1.17.3.2 Deals
12.1.18 NEUSOFT MEDICAL SYSTEMS CO., LTD.
12.1.18.1 Business overview
12.1.18.2 Recent developments
12.1.18.2.1 Product launches and approvals
12.1.18.2.2 Deals
12.1.19 BRAINLAB SE
12.1.19.1 Business overview
12.1.19.2 Products offered
12.1.19.3 Recent developments
12.1.19.3.1 Product launches and approvals
12.1.19.3.2 Deals
12.1.20 MIRADA MEDICAL
12.1.20.1 Business overview
12.1.20.2 Products offered
12.1.20.3 Recent developments
12.1.20.3.1 Product launches and approvals
12.1.20.3.2 Deals
12.2 OTHER PLAYERS
12.2.1 TRASIS
12.2.2 SOFIE
12.2.3 ITM ISOTOPE TECHNOLOGIES MUNICH SE
12.2.4 POSITRIGO AG
12.2.5 PAIRE
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
